Biblio
“Editorial: computational chemogenomics in drug design and discovery.”, Current topics in medicinal chemistry, vol. 12, p. 1867, 2012.
, “Drug repurposing in chemical genomics: can we learn from the past to improve the future?”, Current topics in medicinal chemistry, vol. 12, pp. 1883–1888, 2012.
, “Divergent Ah receptor ligand selectivity during hominin evolution.”, Mol Biol Evol, 2016.
, “Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death”, Carcinogenesis, vol. 36, pp. S89–S110, 2015.
, “Disruptive chemicals, senescence and immortality”, Carcinogenesis, vol. 36, pp. S19–S37, 2015.
, “Disruptive chemicals, senescence and immortality”, Carcinogenesis, vol. 36, pp. S19–S37, 2015.
, “Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs”, Proceedings of the National Academy of Sciences, vol. 104, pp. 11927–11932, 2007.
“Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in LeukemiaDisclosures”, Blood, vol. 134, no. Supplement_1, pp. 1256 - 1256, 2019.
, “Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors”, Journal of medicinal chemistry, vol. 57, pp. 2524–2535, 2014.
, “Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors”, Molecular Cancer Research, vol. 11, pp. 122–132, 2013.
, “Conformational Modulation of the Farnesoid X Receptor by Prenylflavonoids: Insights from Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), Fluorescence Titration and Molecular Docking Studies.”, Biochim Biophys Acta, 2016.
, “A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib”, Journal of Thoracic Oncology, vol. 14, no. 11, pp. e257 - e259, 2019.
, “Comparison of anti-inflammatory mechanisms of mango ( Mangifera Indica L.) and pomegranate ( Punica Granatum L.) in a preclinical model of colitis”, Molecular Nutrition & Food Research, p. n/a - n/a, 2016.
, “Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.”, Cell Mol Gastroenterol Hepatol, vol. 3, no. 2, pp. 163-173, 2017.
, “Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions”, Carcinogenesis, p. bgv033, 2015.
, “Causes of genome instability: the effect of low dose chemical exposures in modern society”, Carcinogenesis, vol. 36, pp. S61–S88, 2015.
“Binding Properties of the C-terminal Domain of VIAF”, Chemical biology & drug design, vol. 72, pp. 331–336, 2008.
, “Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis”, Carcinogenesis, vol. 36, pp. S184–S202, 2015.
, “Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead”, Carcinogenesis, vol. 36, pp. S254–S296, 2015.
, “The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells”, Cell death & disease, vol. 5, p. e1038, 2014.
, “The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor.”, PLoS One, vol. 5, no. 10, 2010.
, “The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor”, PLoS ONE, vol. 5, no. 10, p. e13128, 2010.
, “The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor”, PLoS One, vol. 5, p. e13128, 2010.
, “Alternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration model.”, Comp Biochem Physiol C Toxicol Pharmacol, vol. 156, no. 2, pp. 121-9, 2012.
,